Citadel Advisors’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Citadel Advisors’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-107,900	Closed	-$4.03M	–	15184
2021 Q2	$4.03M	Sell	107,900 -55,100	-34%	-$1.69M	﹤0.01%	4922
2021 Q1	$4.17M	Buy	163,000 +53,800	+49%	+$1.37M	﹤0.01%	4678
2020 Q4	$2.41M	Buy	109,200 +97,600	+841%	+$2.15M	﹤0.01%	4974
2020 Q3	$209K	Buy	+11,600	New	+$240K	﹤0.01%	8732
2020 Q1	–	Sell	-9,500	Closed	-$209K	–	10457
2019 Q4	$209K	Buy	+9,500	New	+$191K	﹤0.01%	8115
2018 Q3	–	Sell	-13,400	Closed	-$164K	–	9908
2018 Q2	$164K	Buy	+13,400	New	+$168K	﹤0.01%	8024

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Citadel Advisors's DRNA Position: Q4 2021 in Review

Citadel Advisors sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 261,200 shares — an estimated $5.27M sold.

Citadel Advisors first reported a position in DRNA in Q1 2015 and held it in 16 quarters. The position peaked at $44.9M in Q4 2019. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Citadel Advisors reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Citadel Advisors sold 261,200 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $5.27M.
Citadel Advisors first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 16 quarters.
Citadel Advisors's Dicerna Pharmaceuticals, Inc. position peaked at $44.9M in Q4 2019.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.